Holen Sie sich die Stockscreener-App
8.2352
9.52%
0.6552
Schlusskurs vom Vortag:
$7.58
Offen:
$7.79
24-Stunden-Volumen:
4.78M
Relative Volume:
1.21
Marktkapitalisierung:
$852.98M
Einnahmen:
$45.97M
Nettoeinkommen (Verlust:
$-508.80M
KGV:
-1.5028
EPS:
-5.48
Netto-Cashflow:
$-382.65M
1W Leistung:
+20.83%
1M Leistung:
+14.50%
6M Leistung:
-43.61%
1J Leistung:
-63.83%
1-Tages-Spanne:
$7.75
$8.40
1-Wochen-Bereich:
$6.9175
$8.40
52-Wochen-Spanne:
$5.90
$28.18
Intellia Therapeutics Inc Stock (NTLA) Company Profile
Firmenname
Intellia Therapeutics Inc
Sektor
Branche
Telefon
857-285-6200
Adresse
40 ERIE STREET, CAMBRIDGE, MA
Vergleichen Sie NTLA mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
NTLA
Intellia Therapeutics Inc
|
8.235 | 771.70M | 45.97M | -508.80M | -382.65M | -5.48 |
|
ONC
Beone Medicines Ltd Adr
|
257.06 | 26.69B | 3.81B | -644.79M | -669.77M | -6.24 |
|
VRTX
Vertex Pharmaceuticals Inc
|
447.80 | 114.81B | 11.10B | -988.90M | -1.26B | -3.92 |
|
AKTX
Akari Therapeutics Plc Adr
|
1.2213 | 41.83M | 0 | 0 | 0 | 0.00 |
|
VRNA
Verona Pharma Plc Adr
|
83.40 | 6.60B | 0 | -153.72M | -103.81M | -2.00 |
|
REGN
Regeneron Pharmaceuticals Inc
|
494.35 | 65.36B | 14.09B | 4.50B | 2.96B | 39.28 |
Intellia Therapeutics Inc Stock (NTLA) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-04-21 | Hochstufung | Wolfe Research | Peer Perform → Outperform |
| 2025-03-05 | Eingeleitet | H.C. Wainwright | Buy |
| 2025-02-28 | Herabstufung | Goldman | Neutral → Sell |
| 2025-02-28 | Herabstufung | JP Morgan | Overweight → Neutral |
| 2025-01-27 | Herabstufung | Morgan Stanley | Overweight → Equal-Weight |
| 2024-02-23 | Herabstufung | Goldman | Buy → Neutral |
| 2024-02-15 | Eingeleitet | Wolfe Research | Peer Perform |
| 2023-04-13 | Eingeleitet | Canaccord Genuity | Buy |
| 2023-03-21 | Eingeleitet | Bernstein | Outperform |
| 2023-03-14 | Hochstufung | BMO Capital Markets | Market Perform → Outperform |
| 2023-02-01 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2023-01-24 | Hochstufung | Citigroup | Sell → Neutral |
| 2023-01-19 | Herabstufung | JMP Securities | Mkt Outperform → Mkt Perform |
| 2022-10-11 | Eingeleitet | Morgan Stanley | Overweight |
| 2022-09-21 | Eingeleitet | JP Morgan | Overweight |
| 2022-09-01 | Eingeleitet | Citigroup | Sell |
| 2022-06-17 | Eingeleitet | BMO Capital Markets | Market Perform |
| 2022-06-16 | Eingeleitet | BofA Securities | Buy |
| 2022-04-28 | Eingeleitet | Credit Suisse | Outperform |
| 2022-02-18 | Eingeleitet | William Blair | Outperform |
| 2022-02-07 | Hochstufung | Oppenheimer | Perform → Outperform |
| 2022-01-31 | Eingeleitet | Cowen | Outperform |
| 2022-01-07 | Eingeleitet | Piper Sandler | Overweight |
| 2021-10-05 | Eingeleitet | Guggenheim | Buy |
| 2021-09-24 | Eingeleitet | Stifel | Buy |
| 2021-06-28 | Bestätigt | H.C. Wainwright | Buy |
| 2021-06-11 | Eingeleitet | H.C. Wainwright | Buy |
| 2021-05-07 | Hochstufung | ROTH Capital | Neutral → Buy |
| 2021-05-04 | Eingeleitet | RBC Capital Mkts | Outperform |
| 2021-03-04 | Eingeleitet | JMP Securities | Mkt Outperform |
| 2020-12-22 | Herabstufung | Robert W. Baird | Outperform → Neutral |
| 2020-10-27 | Eingeleitet | Truist | Buy |
| 2020-10-14 | Eingeleitet | Wells Fargo | Overweight |
| 2020-09-18 | Eingeleitet | Goldman | Buy |
| 2020-02-28 | Hochstufung | Oppenheimer | Perform → Outperform |
| 2020-02-14 | Herabstufung | Wedbush | Outperform → Neutral |
| 2019-11-01 | Hochstufung | Raymond James | Mkt Perform → Outperform |
| 2019-07-09 | Eingeleitet | Robert W. Baird | Outperform |
| 2019-06-10 | Eingeleitet | ROTH Capital | Neutral |
| 2019-05-03 | Hochstufung | Wedbush | Neutral → Outperform |
| 2019-04-12 | Eingeleitet | Evercore ISI | Outperform |
| 2018-11-02 | Herabstufung | Wedbush | Outperform → Neutral |
| 2018-10-29 | Eingeleitet | Credit Suisse | Neutral |
| 2018-09-21 | Eingeleitet | Raymond James | Mkt Perform |
| 2018-05-15 | Hochstufung | Chardan Capital Markets | Neutral → Buy |
| 2018-03-08 | Eingeleitet | JMP Securities | Mkt Outperform |
| 2017-11-01 | Bestätigt | Jefferies | Buy |
| 2017-06-22 | Fortgesetzt | Jefferies | Buy |
| 2017-03-28 | Eingeleitet | Chardan Capital Markets | Buy |
| 2016-08-05 | Hochstufung | Jefferies | Hold → Buy |
Alle ansehen
Intellia Therapeutics Inc Aktie (NTLA) Neueste Nachrichten
Intellia Therapeutics Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) | NTLA Stock News - GuruFocus
Intellia Therapeutics Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) - The Manila Times
Intellia Therapeutics Expands CRISPR Team: 33,600 RSUs Granted to New Leadership - Stock Titan
How Much Upside is Left in Intellia Therapeutics (NTLA)? Wall Street Analysts Think 398.31% - sharewise
Can CRISPR Build on Casgevy's Success With Its In Vivo Pipeline? - TradingView
(NTLA) Investment Report - news.stocktradersdaily.com
Intellia Therapeutics (NTLA) Price Target Adjusted by Canaccord Genuity | NTLA Stock News - GuruFocus
Intellia Therapeutics (NTLA) Sees Price Target Cut Amid Study Up - GuruFocus
Intellia Therapeutics (NTLA) Sees Price Target Cut Amid Study Updates | NTLA Stock News - GuruFocus
ARK Investment Acquires 226K Shares of Intellia Therapeutics (NT - GuruFocus
Cathie Wood's Ark Invest Continues To Offload Tesla As Elon Musk Moves On From Trump Administration - Benzinga
ARK Investment Acquires 226K Shares of Intellia Therapeutics (NTLA) | NTLA Stock News - GuruFocus
Cathie Wood’s ARK buys Intellia, 10x Genomics, sells Tesla stock By Investing.com - Investing.com Nigeria
Cathie Wood’s ARK buys Intellia, 10x Genomics, sells Tesla stock - Investing.com Australia
Intellia slides after safety concern for Regeneron-partnered gene editing therapy - MSN
StockWatch: Intellia Stumbles on News of Patient’s Severe Liver Toxicity - Genetic Engineering and Biotechnology News
NTLA Stock Down as Patient Faces Adverse Event in Gene Therapy Study - Yahoo Finance
Intellia Therapeutics Stock Plummets After Adverse Event In Gene Editing Therapy Study: But Retail’s Buying The Dip - MSN
Intellia shares tumble on safety signal in gene-editing trial - The Pharma Letter
Intellia stock dips following safety event in Phase III gene therapy trial - Clinical Trials Arena
Intellia Therapeutics (NTLA) Receives Continued 'Buy' Rating fro - GuruFocus
Intellia: Shares Sink on Safety Concern in Phase 3 Trial; Lowering Fair Value to $60 From $75 - Morningstar
ARK Investment Acquires Significant Stake in Intellia Therapeutics (NTLA) | NTLA Stock News - GuruFocus
No-Moat Intellia's Gene-Editing Pipeline Looks Promising for Long-Term, Risk-Tolerant Investors - Morningstar
Intellia Therapeutics (NTLA) Faces Challenges Amid Safety Concer - GuruFocus
Intellia adverse event could resurface questions, says JPMorgan - TipRanks
Intellia Therapeutics (NTLA) Faces Setback with Late-Stage Trial Incident - GuruFocus
Intellia: Heart Disease Safety Setback Triggers SelloffCaution Advised (NASDAQ:NTLA) - Seeking Alpha
Intellia Shares Drop 19% After Safety Signal Emerges in Phase 3 Trial - MSN
Intellia Therapeutics Shares Drop 25 Percent After Liver Stress Reported in Gene-Editing Trial - geneonline.com
Intellia tumbles on liver safety signal for CRISPR therapy - FirstWord Pharma
Intellia Therapeutics Faces Safety and Efficacy Challenges with Nex-Z: Analyst Issues Sell Rating - TipRanks
Intellia filing spurs safety concerns over CRISPR drug - BioPharma Dive
Intellia Therapeutics' Rare Heart Disease Candidate Reports Liver Enzyme Spike In Phase 3 Trial, But Stays On Course - Benzinga
Intellia commercial position in question after safety event. says Goldman - TipRanks
Intellia Plunges in Latest Example of Gene Therapy Troubles - Bloomberg
Intellia Therapeutics (NTLA) Faces Challenges Amid Safety Concerns | NTLA Stock News - GuruFocus
Analysts Brush Off Intellia’s Adverse Event but Gene Therapy Safety Concerns Continue - BioSpace
Intellia Therapeutics (NTLA) Faces Revised Price Target Amid Study Concerns | NTLA Stock News - GuruFocus
Intellia stock holds $45 target despite AE concerns By Investing.com - Investing.com Nigeria
Intellia's stock sinks on gene therapy patient's raised enzyme levels, but analysts keep faith - Fierce Biotech
Intellia Therapeutics (NTLA) Stock Drops After Trial Update | NT - GuruFocus
H.C. Wainwright maintains $30 target on Intellia stock post-safety update - Investing.com
Demystifying Intellia Therapeutics: Insights From 9 Analyst Reviews - Benzinga
Cantor maintains Intellia stock at $65 target despite trial concern By Investing.com - Investing.com India
Intellia stock tumbles on safety concerns By Investing.com - Investing.com Canada
Intellia stock tumbles on safety concerns - Investing.com
Intellia stock down on safety concern for gene editing drug - Seeking Alpha
Wedbush Cuts Price Target on Intellia Therapeutics to $7 From $10, Keeps Neutral Rating - marketscreener.com
NTLA: Intellia Therapeutics Advances Key Clinical Trials | NTLA Stock News - GuruFocus
BofA cuts Intellia stock target to $39, maintains Buy rating By Investing.com - Investing.com India
Finanzdaten der Intellia Therapeutics Inc-Aktie (NTLA)
Umsatz
Nettogewinn
Free Cashflow
ENV
Intellia Therapeutics Inc-Aktie (NTLA) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| Clark Eliana | EVP, Chief Technical Officer |
Mar 04 '25 |
Sale |
8.99 |
679 |
6,104 |
95,369 |
| BASTA JAMES | EVP, General Counsel |
Mar 04 '25 |
Sale |
8.99 |
2,572 |
23,122 |
111,925 |
| Bhanji Muna | Director |
Jan 29 '25 |
Sale |
9.97 |
265 |
2,642 |
19,468 |
| Dube Michael P | VP, Chief Accounting Officer |
Jan 03 '25 |
Sale |
12.18 |
1,372 |
16,711 |
45,640 |
| BASTA JAMES | EVP, General Counsel |
Jan 03 '25 |
Sale |
12.18 |
7,074 |
86,161 |
74,497 |
| Lebwohl David | EVP, Chief Medical Officer |
Jan 03 '25 |
Sale |
12.18 |
9,557 |
116,404 |
87,666 |
| Hicks Derek | EVP, Chief Business Officer |
Jan 03 '25 |
Sale |
12.18 |
6,502 |
79,194 |
59,878 |
| LEONARD JOHN M | President and CEO |
Jan 03 '25 |
Sale |
12.18 |
26,807 |
326,509 |
941,115 |
| Sepp-Lorenzino Laura | EVP, Chief Scientific Officer |
Jan 03 '25 |
Sale |
12.18 |
8,966 |
109,206 |
77,388 |
| Clark Eliana | EVP, Chief Technical Officer |
Jan 03 '25 |
Sale |
12.18 |
7,422 |
90,400 |
64,048 |
1.30%
3.35%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):